A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

NCT03867123 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma (GBM)

Interventions

DRUG: LAM561
RADIATION: RT
DRUG: TMZ

Sponsor

Laminar Pharmaceuticals